MedTrace Logo

Tedizolid Prolonged Treatment for Prosthetic Joint Infections

NCT03378427 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-09-08

No results posted yet for this study

Summary

Pilot study the aim of which is to obtain reliable data on the tolerance, compliance and efficacy of Tedizolid used as prolonged (≥ 6 weeks) monotherapy or in combination therapy for the treatment of patients with orthopedic device infections due to Gram positive cocci.

Conditions

  • Prosthetic Joint Infection

Interventions

DRUG

Tedizolid Phosphate 200 MG [Sivextro]

Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.

Sponsors & Collaborators

  • Eric SENNEVILLE M.D. Ph.D.

    collaborator UNKNOWN

  • Tourcoing Hospital

    lead OTHER

Principal Investigators

  • Eric SENNEVILLE, M.D. Ph. D. · G. Dron Hospital, Tourcoing, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-28
Primary Completion
2020-10-22
Completion
2021-08-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03378427 on ClinicalTrials.gov